Paper 14 - IMMUNOSARC2 (COHORT 7A): A SPANISH SARCOMA GROUP (GEIS) PHASE IB TRIAL OF EPIRUBICIN AND IFOSFAMIDE PLUS NIVOLUMAB IN FIRST LINE OF ADVANCED UNDIFFERENTIATED PLEOMORPHIC SARCOMA (UPS)

Author(s)

• 

  Javier Martín-Broto, MD, PhD

  Medical Oncologist
  Fundación Jiménez Díaz University Hospital
  Madrid, Madrid, Spain

  Slides

Co-Author(s)

• 

  Javier Martinez-Trufero, MD

  Medical Oncologist
  Hospital Universitario Miguel Servet
  Zaragoza, Aragon, Spain
• RD

  ROBERTO DIAZ BEVERIDGE, MD

  HU LA FE
  VALENCIA, Comunidad Valenciana, Spain
• 

  IRENE CARRASCO GARCIA, MD (she/her/hers)

  Medical Oncologist
  HU VIRGEN DEL ROCIO
  SEVILLE, Andalucia, Spain
• 

  David S. Da Silva Moura, MD, PhD

  Molecular Biologist
  INSTITUTO DE INVESTIGACIÓN SANITARIA FUNDACIÓN JIMENEZ DIAZ (IIS-FJD)
  MADRID, Madrid, Spain
• AS

  Ana Sebio García, MD, PhD

  Medical Oncologist
  Hospital de la Santa Creu i Sant Pau, IR Sant Pau
  Barcelona, Catalonia, Spain
• EG

  ENRIQUE GONZALEZ BILLALABEITIA, MD

  Medical Oncologist
  HU DOCE DE OCTUBRE
  MADRID, Madrid, Spain
• RR

  RAFAEL RAMOS ASENSIO, MD

  Hospital Quirón Palmaplanas
  PALMA, Islas Baleares, Spain
• AG

  ANTONIO GUTIERREZ, MD, PhD

  HU SON ESPASES
  PALMA, Islas Baleares, Spain
• JC

  JOSEFINA CRUZ, MD

  Medical Oncologist
  HU CANARIAS
  TENERIFE, Canarias, Spain
• 

  CLAUDIA VALVERDE, MD, PhD (she/her/hers)

  Senior consultant Medical Oncology
  HU VALL D'HEBRON
  BARCELONA, Catalonia, Spain
• PL

  PATRICIO LEDESMA, NA

  SOFPROMED
  PALMA, Islas Baleares, Spain
• 

  NADIA HINDI, MD, MsC

  Medical Oncologist
  Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz (IIS/FJD)
  Madrid, Madrid, Spain